Evidence map›Paper›PMID 33387103›Full record

ArticleTransgenic research2021

Generation of a novel decay accelerating factor (DAF) knock-out rat model using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9), genome editing.

Maria G Detsika, K Goudevenou, A M Geurts, H Gakiopoulou, E Grapsa, Elias A Lianos

Abstract read
PubMed Publisher
In one paragraph

Article in Transgenic research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Maria G Detsika1st Department of Critical Care Medicine and Pulmonary Services, School of Medicine, Evangelismos Hospital, G.P. Livanos and M. Simou Laboratories, National and Kapodistrian University of Athens, 3 Ploutarchou Street, 10675, Athens, Greece. mdetsika@med.uoa.gr.ORCID 0000-0003-4425-235X
K Goudevenou1st Department of Critical Care Medicine and Pulmonary Services, School of Medicine, Evangelismos Hospital, G.P. Livanos and M. Simou Laboratories, National and Kapodistrian University of Athens, 3 Ploutarchou Street, 10675, Athens, Greece.
A M GeurtsDepartment of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA.
H GakiopoulouDepartment of Pathology, University of Athens School of Medicine, Athens, Greece.
E GrapsaDepartment of Nephrology, School of Medicine, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Elias A LianosVeterans Affairs Medical Center and Virginia Tech. Carilion School of Medicine, 1970 Roanoke Blvd., Salem, VA, 24153, USA.
National and Kapodistrian University of Athens · GRMedical College of Wisconsin · USSalem VA Medical Center · US

Funding

Novel Complement-targeted treatment strategies in Renal DiseaseI01BX004333 · VA · SALEM VA MEDICAL CENTER · PI LIANOS, ELIAS · 2020 to 2023
–
BLRD VA I01 BX004333
6 · The paper itself

Abstract

Decay accelerating factor (DAF), a key complement activation control protein, is a 70 kDa membrane bound glycoprotein which controls extent of formation of the C3 and C5 convertases by accelerating their decay. Using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9) genome editing we generated a novel DAF deficient (Daf

Indexed as

Acute Kidney InjuryAlbuminuriaAnimalsAntibodies, Anti-IdiotypicCD55 AntigensComplement ActivationComplement C3-C5 ConvertasesComplement C5CRISPR-Cas SystemsGene Knockout TechniquesHeymann Nephritis Antigenic ComplexHumansPodocytesRatsAntibodies, Anti-IdiotypicCD55 AntigensComplement C3-C5 ConvertasesComplement C5Heymann Nephritis Antigenic ComplexAnti-Fx1AComplementCRISPRDecay accelerating factor (DAF)

Identifiers

PMID33387103
OpenAlexW3114085256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.